Navigation Links
PharmaNet Extends Expiration Time in its Tender Offer and Consent Solicitation
Date:6/29/2011

of a consent to amend the related indenture. The Offer is made solely pursuant to the Offer to Purchase. The Offer is not being made to holders of Notes in any jurisdiction in which the making or acceptance thereof would not be in compliance with the securities, blue sky or other laws of such jurisdiction.

None of the Company, the Dealer Managers and Solicitation Agents, the Information Agent or any other person makes any recommendation as to whether holders of Notes should tender their Notes, and no one has been authorized to make such a recommendation.

Company Information and Forward Looking StatementsPharmaNet is a leading provider of integrated product development services and provides clinical development services, including consulting, Phase I and bioequivalency clinical studies, and Phase II, III and IV clinical development programs, to pharmaceutical, biotechnology, generic drug and medical device companies around the world.

This press release contains forward-looking statements which include, but are not limited to, any statement that may predict, forecast, indicate or imply future results, performance, achievements or events. Forward-looking statements are based upon management's current plans and beliefs or current estimates of future results or trends. These forward-looking statements reflect our current views with respect to future events and are based on assumptions and subject to risks and uncertainties that may cause actual results to differ materially from trends, plans or expectations set forth in the forward-looking statements.

Given these risks and uncertainties, we urge you to read the tender offer materials completely and with the understanding that actual future results may be materially different from what we plan or expect. All of the forward-looking statements made in this press release, including statements related to the Offer, including the Expiration Time,
'/>"/>

SOURCE PharmaNet Development Group, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. PharmaNet Extends Consent Payment Deadline for Notes Tendered in Its Tender Offer and Consent Solicitation
2. PharmaNet Announces Tender Offer and Consent Solicitation
3. PharmaNet to Present More Than 20 Posters at the 2010 American Association of Pharmaceutical Scientists Annual Meeting
4. PharmaNet Development Group Experts to Share Insights at the 9th Annual Partnerships in Clinical Trials Conference in Vienna
5. PharmaNet Development Group Appoints Anthony Maida, Vice President, Clinical Research
6. Stephen Kasay Joins PharmaNet Development Group as Chief Information Officer
7. SEC Closes Investigation of PharmaNet Development Group and Recommends No Action
8. Christopher Brennan Joins PharmaNet Development Group as General Counsel
9. PharmaNet Development Group Provides Financial Update and Announces Geographic Expansion
10. PharmaNet Development Group Clinical Research Experts to Present at Global Professional Meetings in June
11. PharmaNet Development Group Gives Notice of Anticipated Fundamental Change and Merger to Holders of Its Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... (PRWEB) April 17, 2015 CIO Review ... for its 20 Most Promising Pharma and Life Science ... MMIS’s MediSpend global compliance software platform for life sciences ... selected by a panel of experts and members of ... entrepreneurship. “MMIS’s MediSpend Platform has been on our radar ...
(Date:4/17/2015)... TX (PRWEB) April 17, 2015 ... and proteomics technologies, announced today that it is ... system, an innovative multiplex PCR based targeted sequencing ... resolution sequence analysis, that enables accurate detection of ... Relay-PCR™ and Omega-Primer™ technologies. The company will collaborate ...
(Date:4/16/2015)... Cytokinetics, Incorporated (Nasdaq: CYTK) announced today ... on Thursday, April 30, 2015 at 4:00 PM Eastern ... a conference call at 4:30 PM Eastern Time to ... for the future. , The conference call will be ... and in the Investor Relations section of Cytokinetics’ website ...
(Date:4/16/2015)... Streetsboro, Ohio (PRWEB) April 16, 2015 ... Safety Index, overexertion involving an outside source was ... injuries. This includes injuries related to lifting, pushing, ... $15.1 billion in direct costs. The David Round ... Round is committed to working hard to develop ...
Breaking Biology Technology:MMIS Chosen by CIO Review as Top 20 Most Promising Pharma and Life Science Technology Solution Providers 2015 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 2LC Sciences Seeks Beta Testers of Targeted Sequencing Method Ahead of Q4 Launch 3Cytokinetics to Announce First Quarter Results on April 30, 2015 2Cytokinetics to Announce First Quarter Results on April 30, 2015 3The David Round Company Helps Companies Meet OSHA Standards by Combining Safety, Ergonomics, and Productivity 2
... About 15 years ago, MIT professors Robert Langer ... programmable, wirelessly controlled microchip that would deliver drugs after ... researchers and scientists from MicroCHIPS Inc. reported that they ... doses of an osteoporosis drug normally given by injection. ...
... Researchers at the Wyss Institute for Biologically Inspired Engineering ... from DNA that could potentially seek out specific cell ... deliver important molecular instructions, such as telling cancer cells ... own immune system, the technology might one day be ...
... ORLANDO, Fla., Feb. 16, 2012   GeneLink ... biotech company, has completed the sale of the ... Life Sciences, Inc. (GeneWize)  to Capsalus Corp. (OTCBB: ... and wellness marketplace.  As previously disclosed, GeneLink and ...
Cached Biology Technology:Successful human tests for first wirelessly controlled drug-delivery chip 2Successful human tests for first wirelessly controlled drug-delivery chip 3Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 2Harvard's Wyss Institute develops DNA nanorobot to trigger targeted therapeutic responses 3GeneLink Biosciences Completes Sale of GeneWize Life Sciences 2
(Date:4/2/2015)... In the current eight ... the strongest competitors, showing outstanding performance in recognition ... is capable of a throughput of 5.000.000 fingerprints ... be ten times faster than most competitors and ...      (Photo: http://photos.prnewswire.com/prnh/20150402/738673-a ) , ...
(Date:4/2/2015)... 2015 According to preliminary estimates ... somewhat higher than 125 MSEK. This exceeds the guidance ... that revenues for Q1 2015 would be in line ... Q4 2014. The operating result for the first quarter ... interim report will as previously communicated be published on ...
(Date:4/1/2015)... 2015  NXT-ID, Inc. (NASDAQ: NXTD ) ("NXT-ID" ... the growing mobile commerce market, announces the second shipment ... underway to early access pre-order customers. ... retail outlets including Walmart, Target, AT&T, Dunkin, Donuts, Stop ... accepted at all outlets and very easy to use. ...
Breaking Biology News(10 mins):DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 2DERMALOG AFIS Emerges as Performance Winner in NIST Benchmark Test 3Fingerprint Cards Revises Revenues for Q1 2015 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 2NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 3NXT-ID Reports Second Shipment of Wocket Smart Wallets Underway to Early Access Pre-order Customers and Provides User Feedback 4
... Calif., June 6, 2012  Amarantus BioSciences, Inc. (OTCBB: ... products for the treatment of Parkinson,s disease and ... today announced that it has been selected to ... Conference in New York City at Le Park ...
... A rose by any other name would smell as ... the chemical components of its fragrance or discovering where its ... biology, an organism,s scientific (taxonomic) name is the key to ... genetic, ecological, and agricultural particulars of every known plant -- ...
... /PRNewswire-iReach/ -- As a driving force behind today,s ... look for ways to expand its employee time ... efforts, uAttend is pleased to announce that TimeClockDeals.com is ... software services. TimeClockDeals.com is a leading retailer ...
Cached Biology News:Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA)122nd Conference in New York City 2Amarantus BioSciences to Present at the National Investment Banking Association's (NIBA)122nd Conference in New York City 3New release of Web-based resource resolves confusion over plant names 2New release of Web-based resource resolves confusion over plant names 3uAttend Time Tracking Solutions Available at TimeClockDeals.com 2
GOAT ANTI HUMAN PSA (ISOFORM 1)...
... Immunogen: Synthetic peptide derived from the N-terminal ... ZO-1. Specificity: Specific for the N-terminus ... Reactivity: Human Dog Rat Mouse (positive controls: ... mouse liver heart blood vessel and brain ...
p-Raf-1 (Ser 338/Tyr 341)-R...
Human/Mouse APLP-1 MAb (Clone 354020) ENTREZ GeneID: 333...
Biology Products: